Louisa A Messenger1, Caryn Bern2. 1. Faculty of Infectious Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 2. Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: Congenital transmission is an important route of Trypanosoma cruzi infection, both in Latin America and internationally, with considerable populations of infected women of child-bearing age residing in the United States and Europe. This review examines recent literature on congenital Chagas disease, with a focus on the changing clinical spectrum and potential new diagnostic tools. RECENT FINDINGS: Vertical transmission occurs in approximately 5-10% of births from T. cruzi-infected mothers. Historically, congenital Chagas disease was associated with high levels of neonatal morbidity and mortality. Bolivian birth cohort data from the early 1990s to the present indicate that the incidence of symptomatic neonatal disease has declined. Treatment with trypanocides is greater than 90% effective and well tolerated in infants. Current programs face challenges from the multistep screening algorithm, low sensitivity of microscopy and high loss to follow-up. SUMMARY: Congenital Chagas disease remains an important contributor to the global disease burden because of T. cruzi. PCR and related molecular techniques represent the most sensitive diagnostic modalities for early detection but require further optimization for resource-limited settings. Several novel diagnostic tests show promise for the future but further validation and adaptation to field settings are needed.
PURPOSE OF REVIEW: Congenital transmission is an important route of Trypanosoma cruzi infection, both in Latin America and internationally, with considerable populations of infected women of child-bearing age residing in the United States and Europe. This review examines recent literature on congenital Chagas disease, with a focus on the changing clinical spectrum and potential new diagnostic tools. RECENT FINDINGS: Vertical transmission occurs in approximately 5-10% of births from T. cruzi-infected mothers. Historically, congenital Chagas disease was associated with high levels of neonatal morbidity and mortality. Bolivian birth cohort data from the early 1990s to the present indicate that the incidence of symptomatic neonatal disease has declined. Treatment with trypanocides is greater than 90% effective and well tolerated in infants. Current programs face challenges from the multistep screening algorithm, low sensitivity of microscopy and high loss to follow-up. SUMMARY:Congenital Chagas disease remains an important contributor to the global disease burden because of T. cruzi. PCR and related molecular techniques represent the most sensitive diagnostic modalities for early detection but require further optimization for resource-limited settings. Several novel diagnostic tests show promise for the future but further validation and adaptation to field settings are needed.
Authors: Laura Francisco-González; Alba Rubio-San-Simón; María Isabel González-Tomé; Ángela Manzanares; Cristina Epalza; María Del Mar Santos; Teresa Gastañaga; Paloma Merino; José Tomás Ramos-Amador Journal: PLoS One Date: 2019-07-10 Impact factor: 3.240
Authors: Cynthia M Cascabulho; Marcelo Meuser-Batista; Kelly Cristina G de Moura; Maria do Carmo Pinto; Thabata Lopes Alberto Duque; Kelly C Demarque; Ana Carolina Ramos Guimarães; Pedro Paulo de Abreu Manso; Marcelo Pelajo-Machado; Gabriel M Oliveira; Solange L De Castro; Rubem Fs Menna-Barreto Journal: Mem Inst Oswaldo Cruz Date: 2020-02-14 Impact factor: 2.747
Authors: Helen Mahoney West; Carly E Milliren; Olivera Vragovic; Julia R Köhler; Christina Yarrington Journal: PLoS One Date: 2021-02-26 Impact factor: 3.240
Authors: Sarah M Bartsch; Owen J Stokes-Cawley; Pierre Buekens; Lindsey Asti; Maria Elena Bottazzi; Ulrich Strych; Patrick T Wedlock; Elizabeth A Mitgang; Sheba Meymandi; Jorge Abelardo Falcon-Lezama; Peter J Hotez; Bruce Y Lee Journal: Vaccine Date: 2020-03-12 Impact factor: 3.641
Authors: Melissa D Klein; Freddy Tinajeros; María Del Carmen Menduiña; Edith Málaga; Beth J Condori; Manuela Verástegui; Federico Urquizu; Robert H Gilman; Natalie M Bowman Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Leny Sanchez; Louisa A Messenger; Tapan Bhattacharyya; Robert H Gilman; Holger Mayta; Rony Colanzi; Ricardo Bozo; Manuela Verástegui; Michael A Miles; Caryn Bern Journal: Trans R Soc Trop Med Hyg Date: 2022-01-19 Impact factor: 2.455